By the end of 2017, CTS has secured three source plasma partners and continues to seek additional partners in the plasma industry in order to continue to diversify CTS’s revenue stream.
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
In October, due to demand from existing healthcare partners, CTS began testing blood donors for anti...